Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

Rhea-AI Summary

Kamada (NASDAQ: KMDA) will release its fiscal year and fourth quarter 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. Management will host an investor conference call at 8:30am Eastern Time the same day and will webcast the discussion live.

Investors may join by phone (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) using conference ID 13758519 or via the live webcast link provided by the company.

Key Figures

Fiscal year end: December 31, 2025 Earnings release date: March 11, 2026 Conference call time: 8:30am Eastern Time +1 more

4 metrics

Fiscal year end December 31, 2025 Period covered by upcoming FY and Q4 2025 results

Earnings release date March 11, 2026 Scheduled FY and Q4 2025 results release before U.S. market open

Conference call time 8:30am Eastern Time Time of management call to discuss FY and Q4 2025 results

US dial-in number 1-877-407-0792 Domestic U.S. access number for earnings call

Market Reality Check

Price: $8.93 Vol: Volume 42,767 is below th...

low vol

$8.93 Last Close

Volume Volume 42,767 is below the 20-day average of 72,522, indicating subdued trading ahead of the earnings date announcement. low

Technical Price at $8.93 is trading above the 200-day MA of $7.34 and sits 4.49% below the 52-week high.

Peers on Argus

KMDA slipped 1.54% while peers were mixed: EBS up 4.32%, CGC up 0.47%, ETON down...

1 Up 1 Down

KMDA slipped 1.54% while peers were mixed: EBS up 4.32%, CGC up 0.47%, ETON down 1.58%, EOLS down 1.9%, AQST up 0.73%. Momentum data show EOLS up 14.77% and AQST down 1.70%, suggesting stock-specific rather than broad sector action.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Forward guidance	Positive	+5.8%	Issued 2026 revenue and adjusted EBITDA guidance with double-digit growth targets.
Dec 18	Commercial contract	Positive	+2.9%	Announced $10–$14M extension of Canadian supply tender securing future sales.
Dec 08	Trial discontinuation	Negative	-4.9%	Discontinued Phase 3 InnovAATe inhaled AAT trial after futility analysis.
Nov 10	Earnings update	Positive	+5.4%	Reported strong Q3 and nine‑month 2025 results with >30% profitability growth.
Nov 04	Clinical milestone	Positive	-3.2%	First patient enrolled in SHIELD CYTOGAM trial for CMV prevention in transplant.

Pattern Detected

Recent news has typically seen the stock move in the same direction as the apparent tone of the announcement, with only one divergence event in the last five releases.

Recent Company History

Over the last several months, Kamada reported strong Q3 2025 results with double‑digit revenue and profitability growth, followed by positive commercial updates like a $10–$14 million Canadian tender extension and detailed 2026 revenue and EBITDA guidance. A negative clinical event occurred with the discontinuation of the InnovAATe Phase 3 inhaled AAT trial, while another release highlighted first‑patient enrollment in the CYTOGAM SHIELD trial. Today’s FY and Q4 2025 earnings date fits into this pattern of frequent operational and financial updates.

Market Pulse Summary

This announcement schedules Kamada’s FY and Q4 2025 results for March 11, 2026, with a conference ca...

Analysis

This announcement schedules Kamada’s FY and Q4 2025 results for March 11, 2026, with a conference call at 8:30am Eastern Time. In recent months, investors have reacted noticeably to the company’s financial reports, guidance, and clinical milestones, including strong 2025 results and a discontinued Phase 3 trial. Ahead of the call, key watchpoints include revenue and adjusted EBITDA versus prior guidance and any updated commentary on growth drivers across Kamada’s plasma-derived and distribution businesses.

AI-generated analysis. Not financial advice.

Company to Host Conference Call at 8:30am ET

REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026.

Kamada’s management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689- 8263 (International) using conference I.D. 13758519. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1751343&tp_key=e8c73d1516.

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its specialty plasma therapies products portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, including six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two types of equine-based anti-snake venom products. Second, distribution of third parties' pharmaceutical products in Israel & MENA through in-licensing partnerships, mainly through the launch of several biosimilar products in Israel. Third, the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Forth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

FAQ

When will Kamada (KMDA) report fiscal year and Q4 2025 results?

Kamada will release fiscal year and Q4 2025 results on March 11, 2026, before U.S. market open. According to the company, management will discuss results and take questions during a conference call at 8:30am ET the same day.

How can investors join Kamada's (KMDA) March 11, 2026 conference call?

Investors can join by phone using conference ID 13758519 or the live webcast link. According to the company, U.S., Israel, and international dial-in numbers are provided for participation.

What is the webcast link for Kamada's (KMDA) March 11, 2026 investor call?

The live webcast will be available at the company's provided URL for the March 11 call. According to the company, the webcast will stream management's discussion and the Q&A session for investors.

What time is Kamada's (KMDA) investor call on March 11, 2026 and what will be covered?

The investor call begins at 8:30am Eastern Time on March 11, 2026. According to the company, management will discuss the fourth quarter and fiscal year 2025 financial results and answer investor questions.

Will Kamada (KMDA) discuss guidance or forward-looking information on the March 11, 2026 call?

The notice confirms a results discussion and Q&A but does not specify guidance details. According to the company, management will present financial results and respond to investor questions during the webcast and call.